Literature DB >> 16687856

The effects of biocides (antiseptics and disinfectants) on the endospores of Rhinosporidium seeberi.

S N Arseculeratne1, D N Atapattu, P Balasooriya, R Fernando.   

Abstract

No data exists on the activity of biocides (antiseptics and disinfectants) on Rhinosporidium seeberi that causes rhinosporidiosis in humans and animals. On account of the inability to culture R. seeberi, in vitro, dyes were used to assess the morphological integrity and viability of biocide-treated endospores that are considered to be the infective stage of this pathogen. Evan's Blue (EvB) identifies the morphological integrity of the endospores while MTT (3-[4, 5-dimethylthiazol-2yl]-2, 5-diphenyl tetrazolium bromide) identifies metabolic activity through its reduction by cellular dehydrogenases to microscopically visible deposits of insoluble formazan. MTT-negativity has earlier been shown to correlate with absence of growth of yeast and mycelial fungi in culture and could thus indicate the loss of viability of MTT-negative rhinosporidial endospores. Hydrogen peroxide, glutaraldehyde, chloroxylenol, chlorhexidine, cetrimide, thimerosal, 70% ethanol, iodine in 70% ethanol, 10% formalin, povidone-iodine, sodium azide and silver nitrate were tested on freshly-harvested endospores and all biocides caused metabolic inactivation with or without altered structural integrity as shown by absence of MTT-staining after 3, 24 or 36 hour after exposure, while EvB stained only the endospores treated with sodium azide, ethanol, thimerosal, chloroxylenol, glutaraldehyde and hydrogen peroxide. With clinically useful biocides - chlorhexidine, cetrimide-chlorhexidine, 70% ethanol, povidone-iodine and silver nitrate, a total period of exposure of endospores to the biocide, for seven minutes, produced metabolic inactivation of the endospores. Anti-rhinosporidial antiseptics that could be used in surgery on rhinosporidial patients include povidone-iodine in nasal packs for nasal and naso-pharyngeal surgery, chlorhexidine and cetrimide-chlorhexidine on the skin, while povidone-iodine and silver nitrate could have application in ocular rhinosporidiosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16687856     DOI: 10.4103/0255-0857.25176

Source DB:  PubMed          Journal:  Indian J Med Microbiol        ISSN: 0255-0857            Impact factor:   0.985


  7 in total

1.  Identification of limiting factors for the optimum growth of fusarium oxysporum in liquid medium.

Authors:  Shilpi Srivastava; Neelam Pathak; Prachi Srivastava
Journal:  Toxicol Int       Date:  2011-07

2.  External dacryocystorhinostomy for isolated lacrimal sac rhinosporidiosis - A suitable alternative to dacryocystectomy.

Authors:  Nandini Bothra; Suryasnata Rath; Ruchi Mittal; Devjyoti Tripathy
Journal:  Indian J Ophthalmol       Date:  2019-05       Impact factor: 1.848

3.  Rhinosporidiosis of the lacrimal sac in a tertiary care hospital of India - A retrospective case study.

Authors:  Sharmistha Behera; Ravindra Kumar Chowdhury; Jayashree Dora
Journal:  Indian J Ophthalmol       Date:  2022-05       Impact factor: 2.969

4.  Oculosporidiosis.

Authors:  Nidhi Pandey; A K Chandrakar; M L Garg; Santosh Singh Patel
Journal:  Indian J Ophthalmol       Date:  2008 Jan-Feb       Impact factor: 1.848

5.  Infestation of the lacrimal sac by Rhinosporidium seeberi: a clinicopathological case report.

Authors:  Bipasha Mukherjee; Ashwin Mohan; V Sumathi; Jyotirmay Biswas
Journal:  Indian J Ophthalmol       Date:  2013-10       Impact factor: 1.848

6.  Ocular rhinosporidiosis mimicking conjunctival squamous papilloma in Kenya - a case report.

Authors:  Stephen Gichuhi; Timothy Onyuma; Ephantus Macharia; Joy Kabiru; Alain M'bongo Zindamoyen; Mandeep S Sagoo; Matthew J Burton
Journal:  BMC Ophthalmol       Date:  2014-04-08       Impact factor: 2.209

7.  Partial regression of large anterior scleral staphyloma secondary to rhinosporidiosis after corneoscleral graft - a case report.

Authors:  Elaine Fiod Costa; Luciano Moreira Pinto; Marcos Adriano Garcia Campos; Thais Mota Gomes; Gyl Eanes Barros Silva
Journal:  BMC Ophthalmol       Date:  2018-02-27       Impact factor: 2.209

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.